Key facts
- This page summarizes Eiry Roberts's Form 4 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 Feb 2022, 18:52.
Eiry Roberts - 31 Jan 2022 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- NBIX
- Reported as of
- 31 Jan 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Feb 2022, 18:52:47 UTC
- Prior SEC filing
- 12 Jan 2022
- Next SEC filing
- 09 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Darin Lippoldt, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eiry Roberts filed Form 4 for NEUROCRINE BIOSCIENCES INC (NBIX) on 02 Feb 2022.
Change
- Previous filing in this sequence was filed on 12 Jan 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NBIX
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +75,411
- Change %
- Price
- $0.000000
- Shares after
- 75,411
- Date
- 31 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 75,411
- Exercise price
- $79.02
- Footnotes
- F1
NBIX
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +11,074
- Change %
- Price
- $0.000000
- Shares after
- 11,074
- Date
- 31 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,074
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
Footnote F2
Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
Footnote F3
The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026.